The beaten-down pharmaceutical stock was revived after it posted an estimates-beating quarter.
Pfizer's 6% dividend yield is enticing, but AbbVie's dividend growth is superior.
The pharmaceutical stock is struggling, but its dividend can be highly valuable to income investors.
Pfizer's pipeline strength is evident, especially with berobenatide and Vyndamax, providing a bridge over the 2028 LOE trough ...
Pfizer's 5.91% yield draws most of the headlines, but a quietly rerated stock and a pipeline loaded with 2026 catalysts are ...
Amazon S3 on MSN
How Pfizer and BioNTech made history with their vaccine
Wondering how Pfizer and partner BioNTech developed a COVID-19 vaccine in record time without compromising safety? Dr Bill ...
Pfizer shareholders are collecting a 6% yield while the stock bleeds value, and the CEO just made a bold promise about ...
The two companies had announced on Monday that NIL had inked an agreement with Pfizer Inc to acquire the trademarks for India ...
Patient investors who buy the stock may be rewarded over the long term.
COVID-19 vaccine formula targets the XFG variant, in line with FDA guidance to more closely match contemporary circulating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results